Clinitech Laboratory Ltd Stock Price Today (NSE: CTLLAB)
Fundamental Score
Clinitech Laboratory Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Clinitech Laboratory Ltd share price today is ₹40.00, up +0.00% on NSE/BSE as of 7 August 2026. Clinitech Laboratory Ltd (CTLLAB) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹9.13 (Cr). The 52-week high for CTLLAB share price is ₹57.00 and the 52-week low is ₹28.55. At a P/E ratio of 21.74x, CTLLAB is currently trading below its industry average P/E of 42.23x. The company has a Return on Equity (ROE) of 4.65% and a debt-to-equity ratio of 0.04.
Clinitech Laboratory Ltd Share Price Chart — NSE/BSE Historical Performance
Clinitech Laboratory Ltd share price chart: -4.76% return over the past month. 52-week high ₹57.00, 52-week low ₹28.55.
Clinitech Laboratory Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 0.00 (Cr) | |
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 0.00 (Cr) | |
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 0.00 (Cr) | |
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 1.20K (Cr) | |
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 1.20K (Cr) | |
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 0.00 (Cr) | |
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | 1.20K (Cr) | |
| ₹41.50 | ₹41.50 | ₹41.50 | ₹41.50 | 0.00 (Cr) | |
| ₹41.50 | ₹41.50 | ₹41.50 | ₹41.50 | 0.00 (Cr) | |
| ₹41.50 | ₹41.50 | ₹41.50 | ₹41.50 | 0.00 (Cr) |
Clinitech Laboratory Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹40.00 | ₹40.00 | ₹40.00 | ₹40.00 | +0.00% | |
| ₹42.00 | ₹42.00 | ₹40.00 | ₹40.00 | -4.76% | |
| ₹37.80 | ₹45.60 | ₹37.80 | ₹42.00 | +11.11% | |
| ₹41.00 | ₹41.50 | ₹37.30 | ₹37.80 | -7.80% | |
| ₹36.00 | ₹45.84 | ₹36.00 | ₹40.00 | +11.11% | |
| ₹35.35 | ₹42.24 | ₹32.20 | ₹35.00 | -0.99% | |
| ₹30.70 | ₹47.15 | ₹30.70 | ₹44.00 | +43.32% | |
| ₹41.50 | ₹43.50 | ₹28.55 | ₹34.89 | -15.93% | |
| ₹43.39 | ₹43.40 | ₹37.50 | ₹42.10 | -2.97% | |
| ₹44.64 | ₹44.64 | ₹40.00 | ₹41.90 | -6.14% | |
| ₹43.90 | ₹43.90 | ₹38.00 | ₹42.52 | -3.14% | |
| ₹50.02 | ₹57.00 | ₹41.80 | ₹46.20 | -7.64% |
AI Research Briefing
Powered by Gemini · 2026-04-15
Micro-cap healthcare play hinges entirely on promoter's actions; high risk, potentially high reward, liquidity a major concern.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Clinitech Laboratory changed its market maker from SVCM Securities to Kalpalabdhi Financials, effective April 10, 2026. Promoter Jagdish Umakant Nayak acquired 9,600 shares on March 30, 2026, increasing the promoter group's holding to 64.62%. This follows a series of open market purchases by the promoter in March.
CORE STORY (THE REAL GAME)
Promoter consolidation play in a micro-cap healthcare service provider. Market is betting on the promoter's ability to turn around or scale the business, or prepping it for a larger strategic move.
- Promoter stake increase signals confidence
- Healthcare sector growth provides a tailwind
- Change in market maker
- Significant order wins
- Improved financial performance
- Strategic partnerships or acquisitions
- Extreme illiquidity
- Micro-cap governance risk
- Negative free cash flow
Promoter increased stake by 0.84%
Indian healthcare sector projected for strong growth
No, Free Cash Flow 5Y: ₹-3.61 Cr
Next 3-6 months depend on promoter's actions and ability to improve financial performance. Key is revenue growth and FCF generation.
Primary Thesis Risk
Illiquidity and micro-cap governance can wipe you out.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Clinitech Laboratory Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Clinitech Laboratory Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CTLLAB across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 21.74 vs Industry: 42.23)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (15.81% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (9.57x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (64.20%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (4.65%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (7.27%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-29.41%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-19.81% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (2.57% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-5.25 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.32%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Clinitech Laboratory Ltd vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Clinitech Laboratory Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Clinitech Laboratory LtdClinitech Labor...Selected✓ CTLLAB • 544220 | 34.5/100 | ₹40.00₹40 | ₹9.13₹9.13 | 21.74Average 21.7 Average | 4.65%Poor 4.65% Poor | 7.27%Poor 7.27% Poor | 0.04Excellent 0.0 Excellent | 2.57%Average 2.57% Average | 15.81%Excellent 15.81% Excellent | 0.00% |
Dr Lal PathLabs LtdDr Lal PathLabs... LALPATHLAB • 539524 | 57.7/100 | ₹1905.20₹1905 | ₹28908.91₹28908.91 | 55.39Average 55.4 Average | 22.30%Excellent 22.30% Excellent | 28.00%Excellent 28.00% Excellent | 0.08Excellent 0.1 Excellent | 12.33%Good 12.33% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LtdVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1344.40₹1344 | ₹14307.85₹14307.85 | 82.71Average 82.7 Average | 19.74%Good 19.74% Good | 21.29%Excellent 21.29% Excellent | 0.44Excellent 0.4 Excellent | 15.47%Excellent 15.47% Excellent | 16.66%Excellent 16.66% Excellent | 0.14% |
Metropolis Healthcare LtdMetropolis Heal... METROPOLIS • 542650 | 57.9/100 | ₹582.45₹582 | ₹11858.49₹11858.49 | 60.38Average 60.4 Average | 13.81%Average 13.81% Average | 17.77%Good 17.77% Good | 0.15Excellent 0.1 Excellent | 1.46%Average 1.46% Average | 10.52%Good 10.52% Good | 0.35% |
Thyrocare Technologies LtdThyrocare Techn... THYROCARE • 539871 | 46.7/100 | ₹579.00₹579 | ₹8420.27₹8420.27 | 52.36Average 52.4 Average | 28.40%Excellent 28.40% Excellent | 35.38%Excellent 35.38% Excellent | 0.09Excellent 0.1 Excellent | 8.37%Good 8.37% Good | 10.88%Good 10.88% Good | 1.76% |
Krsnaa Diagnostics LtdKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹527.45₹527 | ₹1777.47₹1777.47 | 17.31Average 17.3 Average | 10.89%Average 10.89% Average | 12.70%Average 12.70% Average | 0.54Good 0.5 Good | -11.13%Poor -11.13% Poor | 11.75%Good 11.75% Good | 0.50% |
Suraksha Diagnostic LtdSuraksha Diagno... SURAKSHA • 544293 | 56.2/100 | ₹252.15₹252 | ₹1359.30₹1359.30 | 42.23Average 42.2 Average | 14.12%Average 14.12% Average | 16.97%Good 16.97% Good | 0.53Good 0.5 Good | 31.68%Excellent 31.68% Excellent | 17.26%Excellent 17.26% Excellent | 0.00% |
One Global Service Provider IncOne Global Serv... ONEGLOBAL • 514330 | 82.2/100 | ₹564.95₹565 | ₹1178.25₹1178.25 | 16.95Average 16.9 Average | 65.27%Excellent 65.27% Excellent | 87.02%Excellent 87.02% Excellent | 0.00Excellent 0.0 Excellent | 97.21%Excellent 97.21% Excellent | 167.02%Excellent 167.02% Excellent | 0.00% |
3B Blackbio Diagnostics Ltd3B Blackbio Dia... 3BBLACKBIO • 532067 | 60.3/100 | ₹1248.10₹1248 | ₹1079.13₹1079.13 | 18.42Average 18.4 Average | 19.77%Good 19.77% Good | 25.48%Excellent 25.48% Excellent | 0.01Excellent 0.0 Excellent | -12.44%Poor -12.44% Poor | -8.95%Poor -8.95% Poor | 0.31% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹239.10₹239 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr Lal PathLabs Ltd share price28908.91 Cr
- Vijaya Diagnostic Centre Ltd share price14307.85 Cr
- Metropolis Healthcare Ltd share price11858.49 Cr
- Thyrocare Technologies Ltd share price8420.27 Cr
- Krsnaa Diagnostics Ltd share price1777.47 Cr
Clinitech Laboratory Ltd PE Ratio History
Historical price-to-earnings ratio for CTLLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.63 | ₹78.86 | 48.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Clinitech Laboratory Ltd Quarterly Performance
Latest quarterly metrics for CTLLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
5.53%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-29.41%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
15.81%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
2.57%
Compounded annual net profit growth over 5 years
Clinitech Laboratory Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CTLLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Clinitech Laboratory Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Clinitech Laboratory Ltd (CTLLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Clinitech Laboratory Ltd
About CTLLAB (Clinitech Laboratory Ltd)
Clinitech Laboratory Ltd is a comprehensive healthcare service provider dedicated to delivering precise and reliable diagnostic solutions. With a steadfast commitment to patient we...ll-being, CTLLAB offers a wide spectrum of advanced laboratory testing, cutting-edge diagnostic imaging, and essential clinical services. Equipped with state-of-the-art technology and staffed by a team of highly skilled and experienced medical professionals, CTLLAB strives to provide timely and accurate results, empowering physicians to make informed decisions and optimize patient care. The organization's unwavering focus on quality assurance and adherence to stringent protocols ensures the highest standards of accuracy and reliability in every test and procedure performed. CTLLAB's extensive network of strategically located facilities provides convenient access to its comprehensive range of services. From routine blood tests to sophisticated molecular diagnostics, the laboratory offers a diverse menu of testing options to meet the evolving needs of its patients and healthcare partners. The diagnostic imaging centers are equipped with advanced modalities, including MRI, CT scans, ultrasound, and X-ray, enabling detailed visualization and assessment of internal structures. CTLLAB further enhances its service offering with ECG clinics, providing convenient access to essential cardiac monitoring. By integrating advanced technology with a patient-centric approach, CTLLAB is dedicated to providing accessible and high-quality healthcare services to the communities it serves. Committed to continuous improvement and innovation, Clinitech Laboratory Ltd actively invests in research and development to stay at the forefront of diagnostic advancements. The organization's robust quality management system ensures that all processes and procedures are rigorously monitored and optimized to maintain the highest standards of accuracy and reliability. CTLLAB is deeply rooted in a culture of integrity, transparency, and ethical practices, earning the trust and confidence of patients, physicians, and healthcare institutions alike. As a trusted healthcare partner, Clinitech Laboratory Ltd remains steadfast in its mission to provide exceptional diagnostic services and contribute to the well-being of the community.
Company Details
Key Leadership
CTLLAB Share Price: Frequently Asked Questions
What is the current share price of Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd (CTLLAB) trades at ₹40.00 on NSE and BSE. Market cap ₹9.13 (Cr). Educational data only.
What is the P/E ratio of Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd has a P/E of 21.74x vs industry average 42.23x.
What is the Bull Run score for Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd has a Bull Run score of 34.5/100 based on 25+ financial parameters.
Does Clinitech Laboratory Ltd pay dividends?
Clinitech Laboratory Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd has ROE of 4.65%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Clinitech Laboratory Ltd?
Clinitech Laboratory Ltd has debt-to-equity of 0.04.
Is Clinitech Laboratory Ltd a good investment?
Bull Run gives Clinitech Laboratory Ltd a score of 34.5/100. This is not investment advice — consult a SEBI-registered advisor.